ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Radiotherapy for intramedullary, leptomeningeal and epidural metastases: outcomes of an unusual and ominous complication.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNon-osseous intraspinal cord canal metastases (ISCM)-intramedullary, leptomeningeal and epidural metastases-are unusual complications with dismal prognosis. This study assessed clinical outcomes, local control (LC) and overall survival (OS) after conventional palliative three-dimensional conformal radiotherapy (3DCRT). METHODS/PATIENTS: We retrospectively reviewed ISCM treated with 3DCRT between 2012 and 2023. Clinical outcomes were evaluated at baseline and one month after radiotherapy using Eastern Cooperative Oncology Group (ECOG), neurological status by Modified McCormick (MMC) scale, analgesic response, and sphincter control. LC, OS and prognostic factors were explored.
resultsThirty-seven cases were included. The median follow-up (FU) was 5.2 months (1.6-8.4). Median age was 59 years (51-63). Intramedullary metastases represented 62% of cases and leptomeningeal and epidural metastases (LEM) 38%. Most patients (73%) received 30 Gy/10 fractions or 20 Gy/4-5 fractions and 27% received 8 Gy single fraction. At one month, 62% of patients showed ECOG improvement or stability, 20% achieved full neurological recovery, 83% experienced pain relief, and 62% preserved sphincter function. No grade 3 toxicity was observed. Radiological evaluation at a median of 59 days showed complete disappearance in 5%, partial reduction in 30%, no changes in 14%, and 51% had no imaging FU. Median OS was 6.6 months (95% CI 3.4-9.9). LEM, small cell lung cancer (SCLC), and baseline MMC grade 3-5 showed worse median OS (3.2, 5.2 and 2.7 months, respectively).
conclusionsPatients with ISCM may benefit from palliative 3DCRT, particularly in terms of neurological and functional stability or improvement, along with pain relief. Independent unfavorable factors for OS are LEM, SCLC, and poor baseline MMC grade.
Indexed as
Identifiers
41790428What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.